You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company is also working on a diagnostic COVID-19 test, called LamPore, that will run on its MinIon and GridIon nanopore sequencing platforms
The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.
The method uses nanopore sequencing to analyze short cell-free DNA fragments from blood, providing results in as little as six hours.
MinIon sequencing identified pathogens and antimicrobial resistance genes in the gut of preterm infants with suspected necrotizing enterocolitis.
In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.
The firm is part of a research consortium that is led by Mount Sinai and includes Fluidigm to develop a device to detect epigenetic signatures of WMD exposure.
Cyclomics, a 2018 spinout from University Medical Center Utrecht, is testing its assay for treatment response and recurrence monitoring in head and neck cancer.
The test will run on Oxford Nanopore's MinIon and will be used as a reflex test when the standard PCR test does not give a clear answer.
The researchers are testing the method in a clinical trial of hospital-acquired pneumonia and are working on tests for meningitis and prosthetic joint infections.